In:
Current Cancer Drug Targets, Bentham Science Publishers Ltd., Vol. 18, No. 2 ( 2018-01-15), p. 188-201
Abstract:
Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because
of frequent local invasion and metastasis. Effective therapeutic agents for these cancers have not been established. Oncolytic viruses (OVs) constitute a novel class of promising, selective anticancer
agents and recent studies have elucidated their unique features. Moreover, clinical trials are demonstrating promising results. Numerous OVs are being tested in preclinical models of hepatocellular
carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for
HCC in clinical trials. Few other OVs have entered clinical testing. Relatively few preclinical studies and clinical trials exist for biliary cancers. In this review, we introduce various approaches using
OVs to treat the intractable hepatobiliary cancers.
Type of Medium:
Online Resource
ISSN:
1568-0096
DOI:
10.2174/1568009617666170330123841
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2018
SSG:
15,3
Permalink
